EP3262035A1 - Alcools d'alcynyle et leurs procédés d'utilisation - Google Patents

Alcools d'alcynyle et leurs procédés d'utilisation

Info

Publication number
EP3262035A1
EP3262035A1 EP16705959.1A EP16705959A EP3262035A1 EP 3262035 A1 EP3262035 A1 EP 3262035A1 EP 16705959 A EP16705959 A EP 16705959A EP 3262035 A1 EP3262035 A1 EP 3262035A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
methyl
compound
hydroxy
ethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16705959.1A
Other languages
German (de)
English (en)
Inventor
Nicole Blaquiere
Georgette Castanedo
Jianwen A. FENG
James John CRAWFORD
Wendy Lee
Xingyu LIN
Baihua Hu
Guosheng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP3262035A1 publication Critical patent/EP3262035A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to inhibitors of NF-kB -inducing kinase (NIK) useful for treating cancer and inflammatory conditions, among others.
  • NIK NF-kB -inducing kinase
  • NF-kB inducing kinase is also known as MAPK kinase kinase 14 (MAP3K14) and is a serine/threonine kinase and a member of the MAPK family. It was originally identified in a two- hybrid screen as a binding partner of TNF receptor (TNFR) associated factor 2 (TRAF2) [See, Malinin, NL, et al., Nature, 1997, 385:540-4].
  • TNFR TNF receptor
  • TNF2 TNF receptor associated factor 2
  • Overexpression of NIK leads to the activation of NF-kB and dominant negative forms of NIK lacking kinase activity were able to inhibit NF-kB activation in response to TNF and IL-1 treatment.
  • NIK has been identified as an important component of the NF-kB signaling pathway.
  • Scientific research has shown that in blocking the NF-kB signaling pathway in cancer cells can cause such cells to stop proliferating, to die, or to become more sensitive to the action of other anti-cancer therapies.
  • NF-kB controls the expression of many genes involved in inflammation and that NF- kB signaling is found to be chronically active in many inflammatory conditions, such as lupus (including systemic lupus erythematosus), rheumatoid arthritis, inflammatory bowel disease, arthritis, sepsis, gastritis and asthma, among others.
  • organic compounds capable of inhibiting NIK and thereby inhibiting, weakening or lessening the undesired or over-activation of the NF-kB signaling pathway can have a therapeutic benefit for the treatment diseases and disorders for which such undesired or over- activation of NF-kB signaling is observed.
  • alkynyl alcohol compounds that are inhibitors of NIK kinase, compositions containing these compounds and methods for treating diseases mediated by NIK kinase such as cancer and inflammatory diseases.
  • ring A is a monocycle or a fused bicycle
  • Q is N or C, wherein when Q is N, then the bond between Ai and Q is not a double bond and the bond between Q and A 4 is not a double bond;
  • Ai is NR 1 , N, S, CR 1 or CHR 1 ;
  • a 2 is NR 2 , N, O, S, CR 2 or CHR 2 ;
  • a 3 is N or C
  • a 4 is N;
  • each R 1 is independently selected from the group consisting of H, halogen, NR a R b , NHC(0)NR a R b , NHS(0) 2 CH 3 , Ci-C 3 alkyl, C 3 -C 7 cycloalkyl, Ci-C 3 alkoxy and 3-11 membered heterocyclyl, wherein the alkyl of R 1 is optionally substituted by F, OH, CN, SH, Ci-C 3 alkoxy or 3-11 membered heterocyclyl; the cycloalkyl of R 1 is optionally substituted by F, OH, CN, SH, CH 3 or CF 3 ; the alkoxy of R 1 is optionally substituted by F, OH, CN or SH; and the heterocyclyl of R 1 is optionally substituted by F, OH, CN, SH, CF 3 or Ci-C 3 alkyl,
  • each R 2 is independently selected from the group consisting of H, NR a R b Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, phenyl and 3-11 membered heterocyclyl, wherein R is optionally substituted by R c ; or 1 2
  • R and R" are taken together with the atoms to which they are attached to form a cyclic group selected from the group consisting of C 3 -C7 cycloalkyl, phenyl and 3- 11 membered heterocyclyl, wherein the cyclic group is optionally substituted by R d ;
  • R 4 is selected from the group consisting of H, Ci-C 6 alkyl, CH 2 F and CH 2 OH;
  • R 4 and R 5 together form a C 3 -C 11 cycloalkyl optionally substituted by R e or a 3- 11 membered heterocyclyl optionally substituted by R e ;
  • one of A5-A8 is N and the remaining are CR 6 or all are CR 6 ;
  • R 6 is selected from the group consisting of H, F, CI, NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, OCH 3 , OCHF 2 , OCH 2 F, OCF 3 , SH, SCH 3 , SCHF 2 , SCH 2 F, CN, CH 3 , CHF 2 , CH 2 F, CH 2 OH, CF 3 , N0 2 and N 3 ;
  • R a is selected from the group consisting of H and Ci-C 6 alkyl optionally substituted by C 1 -C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R b is selected from the group consisting of H, Ci-C 6 alkyl, Ci-C 6 alkoxy, C 3 -C6 cycloalkyl, C(0)R , phenyl and 3-11 membered heterocyclyl wherein R b may be optionally substituted by C 1 -C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R c and R d are each independently selected from the group consisting of halogen, -(X ⁇ o-i- CN, -(XVi-NO,, -(X')o-i-OH, -(X -NH,, -(X -NCHXR 13 ), -(X i- N(R lb )(R la ), -(X 1 )o-i-CF 3 , Ci_C 6 alkyl, Ci_C 6 haloalkyl, Ci_C 6 heteroalkyl, Ci_C 6 alkoxy, Ci_C 6 alkylthio, oxo, -(x i-Q.Ce alkyl, -(x i-Cs-Qo cycloalkyl, -O-C3-C10 cycloalkyl,
  • R e is selected from the group consisting of halogen, OH, Ci-C 6 alkyl and oxo; and R is selected from the group consisting of Ci-C 6 alkyl and C3-C6 cycloalkyl wherein R may be optionally substituted by C1-C3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • the compound is other than a compound selected from the group consisting of
  • Q is C, and the compound is of the formula (II):
  • ring B is a substituted phenyl and Q is C; and the compound is of formula (III):
  • ring A, Ai, A 2 , A3, A 4 , R 4 and R 5 are as defined for formula (II), n is 0, 1 or 2, and each R 6 is independently selected from the group consisting of F, CI, OCH 3 , CH 3 and CF 3 .
  • A9 is O, NR 11 or CR n R 12 , wherein R 11 and R 12 are each independently selected from the group consisting of H, halogen, OH and C 1 -C 3 alkyl;
  • the invention provides for pharmaceutical compositions comprising a compound of formula (I), (II) or (III), and a pharmaceutically acceptable carrier, diluent or excipient.
  • the invention provides for a compounds of formula (I), (II) or (III), or pharmaceutical compositions thereof for use in therapy.
  • the invention provides the use of a compound or pharmaceutical composition for the preparation of a medicament for the treatment of an inflammatory condition.
  • the inventions provides for compounds of formula (I), (II) or (III), and pharmaceutical compositions thereof for the treatment of diseases and disorders, including, cancer, inflammatory conditions, and autoimmune diseases, among others.
  • the invention provides for a method (or use) of compounds of formulae (I), (II) and (III), or pharmaceutical compositions thereof in the treatment of diseases and disorders, such as, for example, cancer, inflammatory conditions, or autoimmune diseases, among others.
  • the invention provides for compounds of formulae (I), (II) and (III), for the preparation of a medicament for the treatment of cancer, inflammatory conditions, or
  • the invention provides for compound intermediates useful in synthesis of compounds of formulae (I), (II) and (III).
  • the invention provides, inter alia, compounds of formulae (I), (II) and (III), and variations thereof, pharmaceutical compositions comprising compounds of formulae (I), (II) and (III), and methods of using such compounds and compositions in treating diseases and disorders related to undesired or overactivation of the NF-kB signaling pathway, such as, for example, certain cancers and inflammatory conditions.
  • compounds of formulae (I), (II) and (III) and variations thereof, pharmaceutical compositions comprising compounds of formulae (I), (II) and (III), and methods of using such compounds and compositions in treating diseases and disorders related to undesired or overactivation of the NF-kB signaling pathway, such as, for example, certain cancers and inflammatory conditions.
  • alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical, wherein the alkyl radical may be optionally substituted independently with one or more substituents described herein.
  • the alkyl radical is one to eighteen carbon atoms (Ci-Cig).
  • the alkyl radical is Co-C 6 , C0-C5, C0-C3, C1-C12, C1-C10 , Ci-Cg, C 6 , C1-C5, C1-C4, or C1-C3.
  • Co alkyl refers to a bond.
  • alkyl groups include methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1 -propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i- propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-l -propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, - C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3
  • substituents for "optionally substituted alkyls" include one to six instances of F, CI, Br, I, OH, SH, CN, NH 2 , N0 2 , N 3 , COOH, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, S0 2 , phenyl, piperidinyl, piperizinyl,or pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted.
  • alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH 2 CH 2 CH 2 CH 2 -.
  • an alkyl (or alkylene) group will have from 1 to 12 carbon atoms, such as 1-8, 1-6 or 1-3 carbon atoms.
  • alkenylene and alkynylene refer to the unsaturated forms of “alkylene” having double or triple bonds, respectively, and typically have from 2 to 12 carbon atoms, such as 2-8, 2-6 or 2-3 carbon atoms.
  • Alkylene", “alkenylene” and “alkynylene” groups may be optionally substituted.
  • heteroalkyl refers to a straight or branched chain monovalent hydrocarbon radical, consisting of the stated number of carbon atoms, or, if none are stated, up to 18 carbon atoms, and from one to five heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized.
  • the heteroatom is selected from O, N and S, wherein the nitrogen and sulfur atoms can optionally be oxidized and the nitrogen heteroatom can optionally be quaternized.
  • the heteroatom(s) can be placed at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule (e.g., -0-CH 2 -CH 3 ).
  • heteroalkyl groups can be optionally substituted.
  • substituents for "optionally substituted heteroalkyls" include one to four instances of F, CI, Br, I, OH, SH, CN, NH 2 , N0 2 , N 3 , COOH, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, S0 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof
  • heteroalkylene means a divalent radical derived from heteroalkyl, as exemplified by -CH 2 CH 2 SCH 2 CH 2 , -CH 2 SCH 2 CH 2 NHCH 3 and -OCH 2 CH 3 .
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy,
  • alkylenedioxy, alkyleneamino, alkylenediamino, and the like may be optionally substituted.
  • Cycloalkyl refers to a non-aromatic, saturated or partially unsaturated hydrocarbon ring group wherein the cycloalkyl group may be optionally substituted with one or more substituents described herein.
  • the cycloalkyl group is 3 to 12 carbon atoms (C 3 -Ci 2 ).
  • cycloalkyl is C 3 -C 6 , C 3 -Cs, C 3 -Cio or C 5 -C10.
  • the cycloalkyl group, as a monocycle is C 3 -Cs, C 3 -C 6 or C 5 -C6.
  • the cycloalkyl group, as a bicycle is C 7 -Ci 2 .
  • the cycloalkyl group, as a spiro system is C 5 -Ci 2 .
  • Examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l- enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, perdeuteriocyclohexyl, 1-cyclohex-l- enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl.
  • Exemplary arrangements of bicyclic cycloalkyls having 7 to 12 ring atoms include, but are not limited to, [4,4], [4,5], [5,5], [5,6] or [6,6] ring systems.
  • Exemplary bridged bicyclic cycloalkyls include, but are not limited to, bicyclo[4.1.0]heptane, bicycle[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[4.1.0]heptane and bicyclo[3.2.2]nonane.
  • spiro cycloalkyl examples include, spiro[2.2]pentane, spiro[2.3]hexane, spiro[2.4]heptane, spiro [2.5] octane and spiro[4.5]decane.
  • substituents for "optionally substituted cycloalkyls" include one to four instances of F, CI, Br, I, OH, SH, CN, NH 2 , N0 2 , N 3 , COOH, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, S0 2 , phenyl, piperidinyl, piperizinyl, and
  • pyrimidinyl wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted.
  • cycloalkylene means a divalent radical derived from a cycloalkyl group.
  • a cycloalkylene group may be optionally substituted.
  • Heterocyclic group “heterocyclic”, “heterocycle”, “heterocyclyl”, or “heterocyclo” are used interchangeably and refer to any monocyclic, bicyclic, or spiro, saturated or unsaturated, aromatic (heteroaryl) or non-aromatic (e.g., heterocycloalkyl), ring system, where the ring atoms are carbon, and at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen. If any ring atom of a cyclic system is a heteroatom, that system is a heterocycle, regardless of the point of attachment of the cyclic system to the rest of the molecule.
  • heterocyclyl includes 3-11 ring atoms ("members", that is, a 3-11 membered heterocycle) and includes monocycles, bicycles, and spiro ring systems, wherein the ring atoms are carbon, and at least one atom in the ring or ring system is a heteroatom selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 1 to 4 heteroatoms.
  • heterocyclyl includes 3- to 7-membered monocycles having one or more heteroatoms selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 4- to 6- membered monocycles having one or more heteroatoms selected from nitrogen, sulfur or oxygen.
  • heterocyclyl includes 3-membered monocycles.
  • heterocyclyl includes 4-membered monocycles. In another example, heterocyclyl includes 5-6-membered monocycles. In one example, the heterocyclyl group includes 0 to 3 double bonds. Any nitrogen or sulfur heteroatom may optionally be oxidized (e.g., NO, SO, S0 2 ), and any nitrogen heteroatom may optionally be quaternized (e.g., [NR 4 ] + Cr, [NR 4 ] + OH ⁇ ). In another example, heterocyclyl includes 3- to 9-membered spiro cycles having one or more heteroatoms selected from nitrogen, sulfur or oxygen.
  • Example heterocycles are oxiranyl, aziridinyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 1 ,2-dithietanyl, 1,3-dithietanyl, pyrrolidinyl, dihydro-lH-pyrrolyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, imidazolidinyl, piperidinyl, piperazinyl, isoquinohnyl, tetrahydroisoquinohnyl, morphohnyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, dihydropyranyl, tetrahydropyranyl,
  • tetrahydroindazolyl 1,1-dioxohexahydrothiopyranyl.
  • 5 -membered heterocycles containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl, including thiazol-2-yl and thiazol-2-yl N-oxide, thiadiazolyl, including l,3,4-thiadiazol-5-yl and 1,2,4- thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and oxadiazolyl, such as l,3,4-oxadiazol-5-yl, and l,2,4-oxadiazol-5-yl.
  • Example 5-membered ring heterocycles containing 2 to 4 nitrogen atoms include imidazolyl, such as imidazol-2-yl; triazolyl, such as l,3,4-triazol-5-yl; 1,2,3- triazol-5-yl, l,2,4-triazol-5-yl, and tetrazolyl, such as lH-tetrazol-5-yl.
  • Example benzo-fused 5- membered heterocycles are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl.
  • Example 6-membered heterocycles contain one to three nitrogen atoms and optionally a sulfur or oxygen atom, for example pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as l,3,4-triazin-2-yl and l,3,5-triazin-4-yl;
  • pyridazinyl in particular pyridazin-3-yl, and pyrazinyl.
  • the pyridine N-oxides and pyridazine N-oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the l,3,4-triazin-2-yl groups, are other example heterocycle groups. Heterocycles may be optionally substituted.
  • substituents for "optionally substituted heterocycles" include one to six instances of F, CI, Br, I, OH, SH, CN, NH 2 , N0 2 , N 3 , COOH, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, S0 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted.
  • heterocyclylene means a divalent radical derived from a heterocyclyl group.
  • a heterocyclylene group may be optionally substituted.
  • Heteroaryl refers to any mono-, bi-, or tricyclic ring system where at least one ring is a 5- or 6- membered aromatic ring containing from 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, and in an example embodiment, at least one heteroatom is nitrogen. See, for example, Lang's Handbook of Chemistry (Dean, J. A., ed.) 13 th ed. Table 7-2 [1985]. Included in the definition are any bicyclic groups where any of the above heteroaryl rings are fused to an aryl ring, wherein the aryl ring or the heteroaryl ring is joined to the remainder of the molecule.
  • heteroaryl includes 4-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen. In another embodiment, heteroaryl includes 5-6 membered monocyclic aromatic groups where one or more ring atoms is nitrogen, sulfur or oxygen.
  • Example heteroaryl groups include thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, tetrazolo[l,5- b]pyridazinyl, imidazol[l,2-a]pyrimidinyl and purinyl, as well as benzo-fused derivatives, for example benzoxazolyl, benzofuryl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoimidazolyl and indolyl.
  • Heteroaryl groups can be optionally substituted.
  • substituents for "optionally substituted heteroaryls" include one to six instances of F, CI, Br, I, OH, SH, CN, NH 2 , N0 2 , N 3 , COOH, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, cyclopropyl, methoxy, ethoxy, propoxy, oxo, trifluoromethyl, difluoromethyl, sulfonylamino, methanesulfonylamino, SO, S0 2 , phenyl, piperidinyl, piperizinyl, and pyrimidinyl, wherein the alkyl, aryl and heterocyclic portions thereof may be optionally substituted.
  • a heterocyclyl group is attached at a carbon atom of the heterocyclyl group.
  • carbon bonded heterocyclyl groups include bonding arrangements at position 2, 3, 4, 5, or 6 of a pyridine ring, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine ring, position 2, 3, 5, or 6 of a pyrazine ring, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole ring, position 2, 4, or 5 of an oxazole, imidazole or thiazole ring, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole ring, position 2 or 3 of an aziridine ring, position 2, 3, or 4 of an azetidine ring, position 2, 3, 4, 5, 6, 7, or 8 of a quino
  • the heterocyclyl group is N-attached.
  • the nitrogen bonded heterocyclyl or heteroaryl group include bonding arrangements at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2- imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • alkoxy refers to those alkyl groups attached to the remainder of the molecule via an oxygen atom. Non-limiting examples include methoxy, ethoxy and propoxy. Alkoxy groups may be optionally substituted, such as by halogen.
  • alkylthio refers to those alkyl groups attached to the remainder of the molecule via a sulfur atom. Non-limiting examples include -SCH 3 , -SCH 2 CH 3 and -SCH 2 CH 2 CH 3 . Alkylthio groups may be optionally substituted, such as by halogen.
  • halo or halogen
  • haloalkyl is meant to include both an “alkyl” and a “haloalkyl” substituent. Additionally, the term “haloalkyl,” is meant to include monohaloalkyl and polyhaloalkyl.
  • aryl means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon ring radical, which can be a single ring or multiple rings (up to three rings) which are fused together and having the stated number of aryl ring atoms.
  • An aryl group can be optionally substituted.
  • a "phenylene” group refers to a divalent radical derived from a phenyl group.
  • a phenylene group may be optionally substituted.
  • Optionally substituted unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 0, 1, 2, 3, 4, or 5 or more) of the substituents listed for that group in which said substituents may be the same or different. That is, an optionally substituted substituent is independent at each occurrence. In an embodiment an optionally substituted group has 1 substituent. In another embodiment an optionally substituted group has 2 substituents. In another embodiment an optionally substituted group has 3 substituents. In another embodiment an optionally substituted group has 4 substituents.
  • Optional substituents for alkyl and cycloalkyl can be a variety of groups including, but not limited to, halogen, oxo, CN, N0 2 , N 3 , OR', perfluoro-Ci_4 alkoxy, unsubstituted cycloalkyl, unsubstituted aryl (e.g., phenyl), unsubstituted heterocyclyl, NR'R", SR', SiR'R"R"', OC(0)R', C(0)R, C0 2 R, CONR'R", OC(0)NRR", NR"C(0)R', NR"'C(0)NR'R", NR"C(0) 2 R', S(0) 2 R ⁇ S(0) 2 NR'R", NR'S(0) 2 R", NR"'S(0) 2 NR'R", amidino, guanidine, (CH 2 )i_ 4 OR', (CH 2 ) !
  • R', R" and R' each independently refer to groups including, for example, hydrogen; unsubstituted Ci- 6 alkyl; unsubstituted heteroalkyl; unsubstituted aryl; aryl substituted with 1-3 halogens, unsubstituted Ci_C 6 alkyl, Ci_ C 6 alkoxy or Ci_C 6 thioalkoxy groups, unsubstituted aryl-Ci-C 4 alkyl groups, and unsubstituted heteroaryl.
  • R' and R" When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring wherein a ring atom is optionally substituted with N, O or S.
  • NR'R is meant to include 1 -pyrrolidinyl and 4- morpholinyl.
  • substituents for aryl and heterocyclyl groups are varied.
  • substituents for aryl and heterocyclyl groups are selected from the group including, but not limited to, halogen, OR', OC(0)R', NR'R", SR', R', CN, N0 2 , C0 2 R, CONR'R", C(0)R', OC(0)NR'R", NR"C(0)R, NR"C(0) 2 R', NR'C(0)NR"R”', S(0)R', S(0) 2 R', S(0) 2 NR'R", NR'S(0) 2 R", N 3 , perfluoro-Ci-C 4 alkoxy, perfluoro-Ci-C 4 alkoxy, (CH 2 )i_ 4 OR', (CH 2 ) 1 .
  • Suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.
  • heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
  • heteroatom refers to O, N or S.
  • heteroatom refers to O or N.
  • chiral refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • Diastereomer refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers can separate under high resolution analytical procedures such as electrophoresis and chromatography.
  • Enantiomers refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • the compounds of the invention can contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
  • optically active compounds i.e., they have the ability to rotate the plane of plane-polarized light.
  • the prefixes D and L, or R and S are used to denote the absolute configuration of the molecule about its chiral center(s).
  • the prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory.
  • a compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another.
  • a specific stereoisomer can also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which can occur where there has been no stereoselection or
  • racemic mixture and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.
  • tautomer or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganization of some of the bonding electrons.
  • stereochemistry In the structures shown herein, where the stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the invention. Where stereochemistry is specified by a solid wedge or dashed line representing a particular configuration, then that stereoisomer is so specified and defined. Unless otherwise specified, if solid wedges or dashed lines are used, relative stereochemistry is intended. If a discrepancy exists between a structure and its name, the structure governs.
  • solvate refers to an association or complex of one or more solvent molecules and a compound of the invention.
  • solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
  • hydrate refers to the complex where the solvent molecule is water.
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functional group on a compound.
  • an “amino- protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound.
  • Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
  • a "hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl.
  • a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality.
  • Common carboxy-protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2- (p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl and the like.
  • protecting groups and their use see P.G.M. Wuts and T.W. Greene, Greene's Protective Groups in Organic Synthesis 4 th edition, Wiley- Interscience, New York, 2006.
  • mammal includes, but is not limited to, humans, mice, rats, guinea pigs, monkeys, dogs, cats, horses, cows, pigs, and sheep.
  • a “subject,” “individual,” or “patient” is a vertebrate.
  • the vertebrate is a mammal.
  • a subject, individual or patient may be in need of a compound of the present invention.
  • salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • salts derived from pharmaceutically- acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like.
  • Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, ⁇ , ⁇ '-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • suitable inert solvent examples include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,
  • the neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • the present invention provides compounds which are in a prodrug form.
  • prodrug refers to those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
  • prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Prodrugs of the invention include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of a compound of the present invention.
  • the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3- methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone and tert-butylglycine.
  • prodrugs are also encompassed.
  • a free carboxyl group of a compound of the invention can be derivatized as an amide or alkyl ester.
  • compounds of this invention comprising free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group into a group such as, but not limited to, a phosphate ester, hemisuccinate, dimethylaminoacetate, or phosphoryloxymethyloxycarbonyl group, as outlined in Fleisher, D. et al., (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Advanced Drug Delivery Reviews, 19: 115.
  • Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
  • Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group can be an alkyl ester optionally substituted with groups including, but not limited to, ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed.
  • Prodrugs of this type are described in J. Med. Chem., (1996), 39: 10.
  • More specific examples include replacement of the hydrogen atom of the alcohol group with a group such as (Ci-C 6 )alkanoyloxymethyl, l-((Ci- C 6 )alkanoyloxy)ethyl, l-methyl-l-((Ci-C 6 )alkanoyloxy)ethyl, (Ci-C 6 )alkoxycarbonyloxymethyl, N-(Ci-C6)alkoxycarbonylaminomethyl, succinoyl, (Ci-C 6 )alkanoyl, alpha-amino(Ci_4)alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl, where each alpha- aminoacyl group is independently selected from the naturally occurring L-amino acids,
  • prodrug derivatives see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of
  • a "metabolite” refers to a product produced through metabolism in the body of a specified compound or salt thereof. Such products can result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
  • Metabolite products typically are identified by preparing a radiolabelled (e.g., 14 C or 3 H) isotope of a compound of the invention, administering it in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples.
  • a detectable dose e.g., greater than about 0.5 mg/kg
  • metabolites In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well known to those skilled in the art.
  • the metabolite products so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. Compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are intended to be within the scope of the present invention.
  • the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replace by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
  • Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as H ("D"), 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 3 2 P, 33 P, 35 S, 18 F, 36 C1, 123 I and 125 I.
  • Certain isotopically labeled compounds of the present invention e.g., those labeled with 3 H or 14 C
  • Tritiated ( 3 H) and carbon-14 ( 14 C) isotopes are useful for their ease of preparation and detectability.
  • Positron emitting isotopes such as 15 0, 13 N, n C, and
  • Isotopically labeled compounds of the present inventions can generally be prepared by following procedures analogous to those disclosed in the Schemes and Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • an isotopically substituted moiety is the following:
  • compound(s) of this invention and “compound(s) of the present invention” and the like, unless otherwise indicated, include compounds of formulae (I), (II) and (III) and stereoisomers (including atropisomers), geometric isomers, tautomers, solvates, metabolites, isotopes, salts (e.g., pharmaceutically acceptable salts), and prodrugs thereof. In some embodiments, solvates, metabolites, isotopes or prodrugs are excluded, or any combination thereof.
  • Treatment refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, stabilized (i.e., not worsening) state of disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, prolonging survival as compared to expected survival if not receiving treatment and remission or improved prognosis.
  • compounds of the invention are used to delay development of a disease or disorder or to slow the progression of a disease or disorder.
  • Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder, (for example, through a genetic mutation) or those in which the condition or disorder is to be prevented.
  • prophylaxis is excluded from the definition of "treatment.”
  • therapeutically effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
  • efficacy can, for example, be measured by assessing the time to disease progression (TTP) or determining the response rate (RR).
  • TTP time to disease progression
  • RR response rate
  • the therapeutically effective amount is an amount sufficient to decrease or alleviate an allergic disorder, the symptoms of an allergic disorder.
  • autoimmune or inflammatory condition e.g., psoriasis or inflammatory bowel disease
  • symptoms of an acute inflammatory reaction e.g. asthma.
  • a autoimmune or inflammatory condition e.g., psoriasis or inflammatory bowel disease
  • an acute inflammatory reaction e.g. asthma
  • therapeutically effective amount is an amount of a chemical entity described herein sufficient to significantly decrease the activity or number of B-cells.
  • inhibiting includes any measurable decrease or complete inhibition to achieve a desired result. For example, there may be a decrease of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, reduction of activity (e.g., NIK activity) compared to normal.
  • NIK activity e.g., NIK activity
  • bioavailability refers to the systemic availability (i.e., blood/plasma levels) of a given amount of drug administered to a patient. Bioavailability is an absolute term that indicates measurement of both the time (rate) and total amount (extent) of drug that reaches the general circulation from an administered dosage form.
  • Inflammatory condition refers to any disease, disorder, or syndrome in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue damage, or loss of tissue function.
  • Inflammation refers to a localized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute, or wall off (sequester) both the injurious agent and the injured tissue. Inflammation is notably associated with influx of leukocytes or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses and from noninfectious means such as trauma or reperfusion following myocardial infarction or stroke, immune response to foreign antigen, and autoimmune responses.
  • cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth or proliferation.
  • a “tumor” comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
  • Autoimmune disease refers to any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents.
  • any limitation discussed with respect to one embodiment of the invention may apply to any other embodiment of the invention.
  • any compound or composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any compound or composition of the invention.
  • ring A is a monocycle or a fused bicycle
  • Q is N or C, wherein when Q is N, then the bond between Ai and Q is not a double bond and the bond between Q and A 4 is not a double bond;
  • Ai is NR 1 , N, S, CR 1 or CHR 1 ;
  • a 2 is NR 2 , N, O, S, CR 2 or CHR 2 ;
  • a 3 is N or C
  • a 4 is N;
  • each R 1 is independently selected from the group consisting of H, halogen, NR a R b , NHC(0)NR a R b , NHS(0) 2 CH 3 , C 1 -C 3 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 3 alkoxy and 3-11 membered heterocyclyl, wherein the alkyl of R 1 is optionally substituted by F, OH, CN, SH, C 1 -C 3 alkoxy or 3-11 membered heterocyclyl; the cycloalkyl of R 1 is optionally substituted by F, OH, CN, SH, CH 3 or CF 3 ; the alkoxy of R 1 is optionally substituted by F, OH, CN or SH; and the heterocyclyl of R 1 is optionally substituted by F, OH, CN, SH, CF 3 or C 1 -C 3 alkyl,
  • each R 2 is independently selected from the group consisting of H, NR a R b , Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, phenyl and 3-11 membered heterocyclyl, wherein R is optionally substituted by R c ; or
  • R" are taken together with the atoms to which they are attached to form a cyclic group selected from the group consisting of C 3 -C7 cycloalkyl, phenyl and 3-11 membered heterocyclyl, wherein the cyclic group is optionally substituted by R d ;
  • R 4 is selected from the group consisting of H, Ci-C 6 alkyl, CH 2 F and CH 2 OH;
  • R 4 and R 5 together form a C 3 -C 11 cycloalkyl optionally substituted by R e or a 3-11 membered heterocyclyl optionally substituted by R e ;
  • one of A5-A8 is N and the remaining are CR 6 or all are CR 6 ;
  • R 6 is selected from the group consisting of H, F, CI, NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, OCH 3 , OCHF 2 , OCH 2 F, OCF 3 , SH, SCH 3 , SCHF 2 , SCH 2 F, CN, CH 3 , CHF 2 , CH 2 F, CH 2 OH, CF 3 , N0 2 and N 3 ;
  • R a is selected from the group consisting of H and Ci-C 6 alkyl optionally substituted by C1-C3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R b is selected from the group consisting of H, Ci-C 6 alkyl, Ci-C 6 alkoxy, C 3 -C 6 cycloalkyl, C(0)R , phenyl and 3-11 membered heterocyclyl wherein R b may be optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R c and R d are each independently selected from the group consisting of halogen, -(X ⁇ o-i- CN, -(X 1 )o-i-N0 2 , -(x i-SFj, -(X')o-i-OH, -(X 1 ) 0 -i-NH 2 , -(X -NCHXR 13 ), -(x i- N(R lb )(R la ), -(X 1 )o-i-CF 3 , Ci_C 6 alkyl, Ci_C 6 haloalkyl, Ci_C 6 heteroalkyl, Ci_C 6 alkoxy, Ci_C 6 alkylthio, oxo, -(x i-Ci-Ce alkyl, -(x i-Cs-Qo cycloalkyl, -O-C 3 _Ci 0 cycloalkyl, membered heterocyclyl, -(x
  • R e is selected from the group consisting of halogen, OH, Ci-C 6 alkyl and oxo; and R is selected from the group consisting of Ci-C 6 alkyl and C 3 -C 6 cycloalkyl wherein R may be optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 .
  • the compound of formula (I) is other than Compound Nos. 1-199 in PCT/EP2014/067872, filed August 22, 2014, or any intermediate disclosed therein. In some embodiments, the compound of formula (I) is other than a compound selected from the group consisting of Compound Nos. lx-199x in Table lx.
  • the compound is of formula (I) where in Q is C. In some embodiments, the compound is of formula (I) where in Q is C, provided that the compound is other than a compound selected from the group consisting of Compound Nos. lx-146x and 148x-199x. In some embodiments, a compound of formula (I) is further defined as a compound of formula (II):
  • ring A is a monocycle or a fused bicycle
  • Ai is NR 1 , N, S, CR 1 or CHR 1 ;
  • a 2 is NR 2 , N, O, S, CR 2 or CHR 2 ;
  • a 3 is N or C
  • a 4 is N; and one, two or three of A1-A4 are N, wherein:
  • each R 1 is independently selected from the group consisting of H, halogen, NR a R b , NHC(0)NR a R b , NHS(0) 2 CH 3 , C1-C3 alkyl, C 3 -C 7 cycloalkyl, Ci-C 3 alkoxy and 3- 11 membered heterocyclyl, wherein the alkyl of R 1 is optionally substituted by F, OH, CN, SH, Ci-C 3 alkoxy or 3-11 membered heterocyclyl; the cycloalkyl of R 1 is optionally substituted by F, OH, CN, SH, CH 3 or CF 3 ; the alkoxy of R 1 is optionally substituted by F, OH, CN or SH; and the heterocyclyl of R 1 is optionally substituted by F, OH, CN, SH, CF 3 or Ci-C 3 alkyl,
  • each R 2 is independently selected from the group consisting of H, NR a R b Ci-C 6 alkyl, C 3 -C 7 cycloalkyl, Ci-C 6 alkoxy, phenyl and 3-11 membered heterocyclyl, wherein R is optionally substituted by R c ; or
  • R and R" are taken together with the atoms to which they are attached to form a cyclic group selected from the group consisting of C 3 -C 7 cycloalkyl, phenyl and 3- 11 membered heterocyclyl, wherein the cyclic group is optionally substituted by R d ;
  • R 4 is selected from the group consisting of H, Ci-C 6 alkyl, CH 2 F and CH 2 OH;
  • R 4 and R 5 together form a C 3 -Cn cycloalkyl optionally substituted by R e or a 3- 11 membered heterocyclyl optionally substituted by R e ;
  • one of A5-A8 is N and the remaining are CR 6 or all are CR 6 ;
  • R 6 is selected from the group consisting of H, F, CI, NH 2 , NHCH 3 , N(CH 3 ) 2 , OH, OCH 3 , OCHF 2 , OCH 2 F, OCF 3 , SH, SCH 3 , SCHF 2 , SCH 2 F, CN, CH 3 , CHF 2 , CH 2 F, CH 2 OH, CF 3 , N0 2 and N 3 ;
  • R a is selected from the group consisting of H and Ci-C 6 alkyl optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R b is selected from the group consisting of H, Ci-C 6 alkyl, Ci-C 6 alkoxy, C 3 -C 6 cycloalkyl, C(0)R , phenyl and 3-11 membered heterocyclyl wherein R b may be optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ;
  • R c and R d are each independently selected from the group consisting of halogen, -(X ⁇ o-i- CN, -(x i-NO,, -(x i-SFj, -(X')o-i-OH, -(x i-NH,, -(x i-NCHXR 13 ), -(x i- N(R lb )(R la ), -(X 1 )o-i-CF 3 , Ci_C 6 alkyl, Ci_C 6 haloalkyl, Ci_C 6 heteroalkyl, Ci_C 6 alkoxy, Ci_C 6 alkylthio, oxo, -(x i-Ci-Ce alkyl, -(x i-Cs-Qo cycloalkyl, -O-C 3 _Ci 0 cycloalkyl, -( ⁇ ⁇ -3-11 membered heterocyclyl, aryl, -C(
  • R e is selected from the group consisting of halogen, OH, Ci-C 6 alkyl and oxo; and R is selected from the group consisting of Ci-C 6 alkyl and C3-C6 cycloalkyl wherein R may be optionally substituted by C1-C3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 .
  • the compound is of formula (II), provided that the compound is other than a compound selected from the group consisting of Compound Nos. lx-146x and 148x-199x.
  • ring A is a monocycle.
  • Ai is N or CHR 1 . In some embodiments, Ai is N.
  • Ai is N
  • a 2 is S and A 3 is C.
  • a 2 is N, O or CHR .
  • a 2 is N. In some embodiments, Ai is S, A 2 is N and A 3 is C. In some embodiments, A 2 is O, Ai is CR 1 , A 2 is O and A 3 is C.
  • Ai is CHR 1 and A 2 is CHR 2 , and ring A is a non-aromatic heterocyle. In some embodiments, Ai is CHR 1 and A 2 is CHR 2 , and ring A is a non-aromatic monocyclic heterocyle. In some embodiments, Ai is CHR 1 and A 2 is CHR 2 , and ring A is a fused bicyclic non-aromatic heterocyle.
  • Ai is CHR 1 ;
  • a 2 is CHR 2 ; and
  • R 1 and R2 are taken together with the atoms to which they are attached to form a C 3 -C 7 cycloalkyl optionally substituted by R d or a 3-11 membered heterocyclyl optionally substituted by R d .
  • R 1 and R 2 together form the following cyclic group, wherein the asterisks indicate the points of ring fusion to ring A, and each cyclic group is optionally substituted by R d :
  • R 1 and 2 are taken together with the atoms to which they are attached to form a moiety of the structure: t , which is optionally substituted by R d , wherein the asterisks indicate the points of ring fusion to ring A.
  • Ai is CR 1 wherein R 1 is selected from the group consisting of NHC(0)NR a R b ; NHS(0) 2 CH 3 ; C 1 -C3 alkyl substituted by Ci-C 3 alkoxy or 3-11 membered heterocyclyl; and 3-11 membered heterocyclyl substituted by Ci-C 3 alkyl.
  • Ai is CR 1 wherein R 1 is NHC(0)NR a R b .
  • R a and R b are independently selected from the group consisting of H and Ci-C 6 alkyl.
  • Ai is CR 1 wherein R 1 is NHS(0) 2 CH 3 . In some embodiments, Ai is CR 1 wherein R 1 is 3-11 membered heterocyclyl substituted by Ci-C 3 alkyl. In some embodiments, Ai is CR 1 wherein R 1 is Ci-C 3 alkyl substituted by Ci-C 3 alkoxy or 3-11 membered heterocyclyl. In som sisting of:
  • Ai is NR 1 , S or CR 1 ; and A 2 is NR 2 , S or CR 2 .
  • A is a monocycle
  • Ai is NR . In some embodiments, Ai is 2
  • a 2 is CR and A 3 is C.
  • R 1 is H or Ci-C 3 alkyl.
  • Ai is CR 1 . In some embodiments, is 1 2 1
  • Ai CR , A 2 is CR and A 3 is N. In some embodiments, Ai is CR and A 6 is CR°. In some of these embodiments, A 2 is CR where R is H or -OCH 3 .
  • Ai is CR 1
  • a 2 is S and A 3 is C.
  • R 1 is other than -NH 2 or -CH 3 .
  • R 1 is H, F or CI.
  • R 1 is NR a R b .
  • R a is H or Ci-C 6 alkyl.
  • R b is H; Ci-C 6 alkyl optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 ; or 3-11 membered heterocyclyl optionally substituted by Ci-C 3 alkoxy, F, OH, CN, SH, CH 3 or CF 3 .
  • R b is C(0)R .
  • R is C 3 -C 6 cycloalkyl optionally substituted by F.
  • R 1 is Ci-C 3 alkyl optionally substituted by F, OH, CN, SH, Ci-C 3 alkoxy or 3-11 membered heterocyclyl; C 3 -C 7 cycloalkyl optionally substituted by F, OH, CN, SH, CH 3 or CF 3 ; or Ci-C 3 alkoxy.
  • R 1 is 3-11 membered heterocyclyl optionally substituted by F, OH, CN, SH, CF 3 or Ci-C 3 alkyl.
  • R 1 is a 5-6 membered heteroaryl optionally substituted by F, OH, CN, SH, CF 3 or Ci-C 3 alkyl.
  • R 1 is selected from the group consisting of:
  • Ai is S. In some embodiments, Ai is S, A 2 is CR and A 3 is C. In some embodiments, R is H. In some embodiments,
  • Ai is NR 1 or CR1 ; and A 2 is NR 2 or CR 2.
  • Ai is NR 1 or CR1 ;
  • a 2 is NR 2 or CR 2 ; and
  • R 1 and R2 are taken together with the atoms to which they are attached to form a C 3 -C 7 cycloalkyl optionally substituted by R d , or a 3-11 membered heterocyclyl optionally substituted by R d .
  • R 1 and R 2 are taken together with the atoms to which they are attached to form a moiety selected from the roup consisting of: wherein the asterisks indicate the points of ring fusion to ring A.
  • a 7 is CR 6 where R 6 is H. In some embodiments, As is CR 6 where R 6 is H or F. In some embodiments, A5 is CR 6 where R 6 is H. In some embodiments, A 6 is CR 6 where R 6 is selected from the group consisting of H, F, OCH 3 and CH 3 . In some embodiments, A 5 , A 6 , A 7 and A 8 are each independently CR 6 where R 6 is, independently at each occurrence, selected from the group consisting of H, F, OCH 3 and CH 3 and n is 0.
  • a compound of formula (I) is further defined as a compound of formula (HI):
  • ring A, Ai, A 2 , A3, A 4 , R and R are as defined for formula (II) or any variation detailed herein, n is 0, 1 or 2, and each R 6 is independently selected from the group consisting of F, CI, OCH 3 , CH 3 and CF 3 .
  • the compound is of formula (III), provided that the compound is other than a compound selected from the group consisting of Compound Nos. lx- 3x, 12x-14x, 16x, 18x-50x, 53x, 57x, 67x-70x, 73x-77x, 84x-140x, 143x-164x and 167x-199x in Table lx.
  • R 4 and R 5 are taken together with carbon to which they are attached to form a Cs-Cio cycloalkyl optionally substituted by R e . In some embodiments, R 4 and R 5 are taken together with carbon to which they are attached to form a 4-9 membered heterocyclyl optionally substituted by R e .
  • a 9 is O, NR 11 or CR n R 12 , wherein R 11 and R 12 are each independently selected from the group consisting of H, halogen, OH and C 1 -C 3 alkyl;
  • R 9 and R 10 are each independently selected from H and R e , or R 9 and R 10 are taken together with the atoms to which they are attached to form a C5-C6 cycloalkyl optionally substituted by R e or a 5-6 membered heterocyclyl optionally substituted by R e .
  • R R together form 0; R and R are each H; and A 9 is NR 11 where R 11 is C 1 -C 3 alkyl.
  • the moiety is selected from the group consisting of:
  • the moiety is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • ring A is a monocycle
  • Ai is NR 1
  • each A 5 , A 6 , A 7 and A 8 is independently CR 6
  • the -C(R 4 )(R 5 )OH moiety is 3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl.
  • ring A is a monocycle
  • Ai is CR 1 wherein R 1 is other than -NH 2 or -CH 3
  • a 2 is S
  • A3 is C
  • each A5, A 6 , A 7 and As is independently CR 6
  • the -C(R 4 )(R 5 )OH moiety is 3-hydroxy-l-methyl-2- oxopyrrolidin-3-yl.
  • ring 1 2 is a monocycle
  • Ai is CR 1 wherein R 1 is other than -NH 2 or -CH 3
  • a 2 is S
  • A3 is C
  • each A5, A 6 , A 7 and As is independently CR 6
  • A is a monocycle, Ai is CR , A 2 is CR , A3 is N,
  • a 6 is CR 6 , and the -C(R 4 )(R 5 )OH moiety is 3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl.
  • Ai is NR , S or CR ; and A 2 is NR , S or CR .
  • a 2 i S or CR provided that the compound is other than a compound selected from the group consisting of Compound Nos. 55x, 78x-83x, 89x, 195x and 197x.
  • the compound of is formula (I), (II) or (III), wherein the -C(R 4 )(R 5 )OH moiety is 3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl. In some embodiments, the compound of is formula (I), (II) or (III), wherein the -C(R 4 )(R 5 )OH moiety is 3-hydroxy-l- methyl-2-oxopyrrolidin-3-yl; provided that the compound is other than a compound selected from the group consisting of Compound Nos.
  • one of A 1 -A4 is N. In some embodiments, A 4 is N. In some embodiments, two of A 1 -A4 is N. For example, in some embodiments, Ai and A 4 are each N. In other embodiments, A3 and A 4 are each N. In any such embodiment, ring B may be phenyl or phenyl independently substituted by one or two R 6 . In some embodiments, A 1 is CR 1 , A 2 is CR 2 , A 3 is N and A 4 is N.
  • R 1 is selected from the group consisting of H, F and CI. In some embodiments, R is selected from the group consisting of H, NH 2 , CH 3 and cyclopropyl. In other embodiments, R 2 is a 1
  • R and R2 together form the following cyclic group, wherein the asterisks indicate the points of ring fusion to ring A, and each c scrap group is optionally substituted by R d :
  • R 1 and R 2 together form the following cyclic group, wherein the asterisks indicate the points of ring fusion to ring A, and each cyclic group is optionally substituted by R d :
  • R d is selected from the group consisting of OH, CN, F, C 1 -C3 alkoxy, -O-Q-C3 alkyl-phenyl, NR a R b , 4-6 membered heterocyclyl, C(0)R , C(0) 2 R and Ci-C 6 alkyl optionally substituted by OH, CN, or 4-6 membered heterocyclyl.
  • ring B is phenyl
  • R c and R d are each independently selected from the group consisting of halogen, -(XV-CN, -(X 1 )o-i-N0 2 , -(x i-SFj, -(X')o-i-OH, -(x i-NH,, i-N(H)(R la ), -(X 1 )o-i-N(R lb )(R la ), -(X 1 ) 0 -i-CF 3 , Ci_C 6 alkyl, Ci_C 6 haloalkyl, Ci_C 6 heteroalkyl, Ci_C 6 alkoxy, Ci_C 6 alkylthio, oxo, -(x i-Ci-Ce alkyl, cycloalkyl,
  • heterocyclyl e.g., a 4-7 membered heterocycloalkyl or a 5-6 membered heteroaryl
  • heterocycloalkyl or a 5-6 membered heteroaryl comprising 0-3 additional heteroatoms selected from N, O and S;
  • Y 1 is O, NR lc or S wherein R lc is H or Ci_C 6 alkyl; wherein any portion of an R c or R d substituent, including R la , R lb and R lc , at each occurrence is each independently further substituted by from 0 to 4 R substituents selected from the group consisting of halogen, CN, N0 2 , OH, NH 2 , -N(Ci_C 6 alkyl) 2 , -NH(Ci_C 6 alkyl), oxo, Ci_C 6 alkyl, Ci_C 6 haloalkyl, Ci_C 6 hydroxyalkyl, Ci_C 6 heteroalkyl, Ci_C 6 alkoxy, Ci_C 6 alkylthio, C3-C7 cycloalkyl, or 3-11 membered hetero
  • a heterocyclyl group contains one to three nitrogen atoms, one oxygen atom, or one sulfur atom, or any combination thereof.
  • a compound of the present invention is defined as any one or more of the following:
  • a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent or excipient.
  • a compound or pharmaceutical composition described herein can be used in therapy, such as the treatment of an inflammatory condition (e.g., lupus, such as systemic lupus erythematosus, extrarenal lupus, or lupus nephritis, COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatitis, endometriosis and transplant rejection).
  • an inflammatory condition e.g., lupus, such as systemic lupus erythematosus, extrarenal lupus, or lupus nephritis
  • COPD rhinitis
  • multiple sclerosis IBD
  • arthritis arthritis
  • rheumatoid arthritis dermatitis
  • endometriosis and transplant rejection e.g.,
  • erythematosus erythematosus, extra-renal lupus, or lupus nephritis, COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatitis, endometriosis and transplant rejection).
  • a method for the treatment of an inflammatory condition in a patient comprising administering an effective amount of a compound or pharmaceutical composition as described herein to the patient.
  • the inflammatory condition can be selected from the group consisting of lupus, such as systemic lupus erythematosus, extra-renal lupus, or lupus nephritis, COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatitis, endometriosis and transplant rejection.
  • [M] is a boronic acid, a boronic ester, or a trifluoroborate salt, in the presence of (a)(i) a palladium(O) catalyst or (a)(ii) a copper catalyst and (b) a base under Suzuki reaction conditions to yield a compound of formula (I).
  • Non- limiting examples of palladium catalysts include Pd(PPh 3 ) 4 , Pd(OAc) 2 and Pd(PPh 3 ) 2 Cl 2 .
  • a non- limiting example of a copper catalyst is copper(II) acetate.
  • bases include sodium carbonate, potassium carbonate and cesium carbonate, or mixtures thereof. In some embodiments, copper(II) acetate and pyridine as the base are employed under Chan-Lam coupling conditions, as is known in the art.
  • the carbon-nitrogen bond in an indazole or an aza-indazole can be formed using Chan-Lam coupling conditions.
  • a variety of organic solvents may be employed, including toluene, THF, dioxane, 1 ,2-dichloroethane, DMF, DMSO and acetonitrile.
  • Reaction temperatures vary depending on conditions but typically range from room temperature to 150°C.
  • the invention provides a compound of Table 1 A and Table IB:
  • the invention provides a compound in the Examples.
  • the compound is selected from Compounds 1-69, and salts thereof. In some embodiments, the compound is selected from Compounds 4, 5, 12, 16, 20, 26, 37, 43, 49, 52, 55, 65 and 67 and salts thereof.
  • the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, WI) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-23, Wiley, N.Y. (1967-2006 ed.), or Beilstein's Handbuch der organishcen chemie, 4, Aufl. Ed. Springer- Verlag, Berlin including supplements also included via the Beilstein online database.
  • Aldrich Chemicals Mowaukee, WI
  • Beilstein's Handbuch der organishcen chemie 4, Aufl. Ed. Springer- Verlag, Berlin including supplements also included via the Beilstein online database.
  • Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column or supercritical fluid chromatography.
  • a single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994; Lochmuller, C. H., J. Chromatogr., 113(3):283-302 (1975)).
  • Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
  • suitable method including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.
  • Diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, -methyl- -phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid.
  • enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, -methyl- -phenylethylamine (amphetamine), and the like
  • acidic functionality such as carboxylic acid and sulfonic acid.
  • the diastereomeric salts may be induced to separate by fractional
  • the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York, 1994, p. 322).
  • Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the pure or enriched enantiomer.
  • a method of determining optical purity involves making chiral esters, such as a menthyl ester, e.g., (-) menthyl chloroformate in the presence of base, or Mosher ester, a-methoxy-a-(trifluoromethyl)phenyl acetate (Jacob, J. Org. Chem.
  • Enriched or purified enantiomers can be distinguished by methods used to distinguish other chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.
  • the absolute stereochemistry of chiral centers and enantiomers can be determined by x-ray crystallography.
  • Positional isomers for example E and Z forms, of compounds of formulae (I), (II) and (III) and intermediates for their synthesis, may be observed by characterization methods such as NMR and analytical HPLC. For certain compounds where the energy barrier for interconversion is sufficiently high, the E and Z isomers may be separated, for example by preparatory HPLC.
  • the compounds with which the invention is concerned are NIK kinase inhibitors, and are useful in the treatment of several diseases, for example, cancer or inflammatory conditions.
  • compositions and medicaments comprising a compound of formula (I), (II), (III) or any variations thereof detailed herein and at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the compositions of the invention can be used for inhibiting NF-kB signaling activity in mammals (e.g., human patients), by for example, inhibiting NIK activity.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the invention provides for pharmaceutical compositions (or medicaments) comprising a compound of formula (I), (II), (III) or any variations thereof detailed herein and a pharmaceutically acceptable carrier, diluent or excipient.
  • the invention provides for preparing compositions (or medicaments) comprising compounds of the invention.
  • the invention provides for administering compounds of formula (I), (II), (III) or any variations thereof detailed herein and compositions comprising compounds of formula (I), (II), (III) or any variations thereof detailed herein to a mammal (e.g., a human patient) in need thereof.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the effective amount of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit NIK activity as required to prevent or treat the undesired disease or disorder, such as for example, neurodegeneration, amyloidosis, formation of neurofibrillary tangles, or undesired cell growth (e.g., cancer cell growth). For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.
  • the therapeutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01-100 mg/kg, alternatively about e.g., 0.1 to 20 mg/kg of patient body weight per day, such as 0.3 to 15 mg/kg/day.
  • the daily does is, in certain embodiments, given as a single daily dose or in divided doses two to six times a day, or in sustained release form. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 mg to about 1,400 mg. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
  • Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • the compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
  • compositions comprising compounds of formula (I), (II), (III) or any variations thereof detailed herein are normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • a typical formulation is prepared by mixing a compound of the present invention and a diluent, carrier or excipient. Suitable diluents, carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • buffers stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing
  • Suitable carriers, diluents and excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water soluble or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like.
  • the particular carrier, diluent or excipient used will depend upon the means and purpose for which a compound of the present invention is being applied.
  • Solvents are generally selected based on solvents recognized by persons skilled in the art as safe (GRAS) to be administered to a mammal.
  • safe solvents are non-toxic aqueous solvents such as water and other non-toxic solvents that are soluble or miscible in water.
  • Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG 400, PEG 300), etc. and mixtures thereof.
  • the formulations can also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • Acceptable diluents, carriers, excipients and stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, aspara
  • a active pharmaceutical ingredient of the invention can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing a compound of formula (I), (II), (III) or any variations thereof detailed herein, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (for example, poly(2- hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides (U.S. Patent No.
  • injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
  • poly-D-(-)-3-hydroxybutyric acid injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
  • the formulations include those suitable for the administration routes detailed herein.
  • the formulations can conveniently be presented in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington: The Science and Practice of Pharmacy: Remington the Science and Practice of Pharmacy (2005) 21 st Edition, Lippincott Williams & Wilkins, Philadelphia, PA. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers, diluents or excipients or finely divided solid carriers, diluents or excipients, or both, and then, if necessary, shaping the product.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier, diluent or excipient.
  • the formulations can be prepared using conventional dissolution and mixing procedures.
  • the bulk drug substance i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent) is dissolved in a suitable solvent in the presence of one or more of the excipients described above.
  • a compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to enable patient compliance with the prescribed regimen.
  • compounds of formulae (I), (II) and (III) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers.
  • the pH of the formulation depends mainly on the particular use and the concentration of compound, but typically ranges anywhere from about 3 to about 8.
  • a compound of formula (I), (II), (III) or any variations thereof detailed herein is formulated in an acetate buffer, at pH 5.
  • the compounds of formulae (I), (II) and (III) are sterile.
  • the compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.
  • Formulations of a compound of the invention suitable for oral administration can be prepared as discrete units such as pills, capsules, cachets or tablets each containing a
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets can optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
  • Tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, e.g., gelatin capsules, syrups or elixirs can be prepared for oral use.
  • Formulations of a compound of the invention intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
  • excipients can be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets can be uncoated or can be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax can be employed.
  • An example of a suitable oral administration form is a tablet containing about 1 mg, 5 mg, 10 mg, 25 mg, 30 mg, 50 mg, 80 mg, 100 mg, 150 mg, 250 mg, 300 mg and 500 mg of the compound of the invention, or any range derivable therein, compounded with about 5-30 mg anhydrous lactose, about 5-40 mg sodium croscarmellose, about 5-30 mg polyvinylpyrrolidone (PVP) K30, and about 1-10 mg magnesium stearate.
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using
  • an example of an aerosol formulation can be prepared by dissolving the compound, for example 5-400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired.
  • a suitable buffer solution e.g. a phosphate buffer
  • a tonicifier e.g. a salt such sodium chloride
  • the solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
  • the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w.
  • the active ingredient can be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients can be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base can include a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
  • the topical formulations can desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulfoxide and related analogs.
  • the oily phase of the emulsions of this invention can be constituted from known ingredients in a known manner. While the phase can comprise merely an emulsifier, it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
  • Emulsifiers and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • Aqueous suspensions of a compound of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • Such excipients include a suspending agent, such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
  • a suspending agent such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropyl
  • the aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives such as ethyl or n-propyl p-hydroxybenzoate
  • coloring agents such as a coloring agent
  • flavoring agents such as sucrose or saccharin.
  • sweetening agents such as sucrose or saccharin.
  • Formulations of a compound of the invention can be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol or prepared as a lyophilized powder.
  • the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils can conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can likewise be used in the preparation of injectables.
  • a time-release formulation intended for oral administration to humans can contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which can vary from about 5 to about 95% of the total compositions (weight:weight).
  • the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
  • an aqueous solution intended for intravenous infusion can contain from about 3 to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which can contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which can include suspending agents and thickening agents.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is preferably present in such formulations in a concentration of about 0.5 to 20% w/w, for example about 0.5 to 10% w/w, for example about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration can be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns (including particle sizes in a range between 0.1 and 500 microns in increments microns such as 0.5, 1, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration can be prepared according to conventional methods and can be delivered with other therapeutic agents such as compounds heretofore used in the treatment of disorders as described below.
  • Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the formulations can be packaged in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water, for injection immediately prior to use.
  • sterile liquid carrier for example water
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
  • the compounds of formulae (I), (II) and (III) inhibit the activity of NIK. Accordingly, in another aspect of the invention the compounds of the invention can be used for the treatment of diseases and disorders in a mammal, for example a human patient, in which the inhibition of NIK in the patient would be therapeutically effective.
  • the compounds of the invention are useful for the treatment of diseases or disorders in a mammal (e.g., a human patient) associated with overactive or undesired NF-kB signaling through, for example, the overactivation of NIK.
  • the compounds of the invention are used to inhibit the activity of NIK, for example in an in vitro assay setting, by contacting said compound of formula (I), (II), (III) or any variations thereof detailed herein with NIK.
  • compounds of formulae (I), (II) and (III) can be used as a control compound in an in vitro assay setting.
  • the compounds of the invention are used to inhibit the undesired signaling of NF-kB, e.g. in an cell proliferation assay, by introducing into a cell a compound of formula (I), (II), (III) or any variations thereof detailed herein.
  • the present invention provides the treatment of diseases or disorders in a mammal (e.g., human patient) associated with overactive or undesired NF-kB signaling (e.g., cancer, inflammatory diseases, among others) said method comprising administering to a mammal (e.g., a human patient) in need thereof a therapeutically effective amount of a compound of the invention.
  • Diseases and disorders treatable according to the methods of this invention include, cancer, inflammatory conditions, autoimmune disease and proliferation induced after medical procedures (e.g., arthritis, graft rejection, inflammatory bowel disease, cell proliferation induced after surgery angioplasty, among others).
  • a mammal e.g., a human patient
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle wherein said compound of the invention is present in an amount to inhibit NF-kB signaling through, for example, but not limited to, inhibition of NIK.
  • a compound of the invention can be used in the treatment of cell proliferative disorders.
  • cancers that may be treated by the compounds of formulae (I), (II) and (III) are selected from the group consisting of Lung (bronchogenic carcinoma (non-small cell lung); Gastrointestinal - rectal, colorectal and colon; Genitourinary tract - kidney (papillary renal cell carcinoma); and skin - head and neck squamous cell carcinoma.
  • compounds of formulae (I), (II) and (III) can be use for the treatment of a cancer selected from the group consisting of head and neck squamous cell carcinomas, histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, papillary renal cell carcinoma, liver cancer, gastric cancers, colon cancer, leukemias, lymphomas, multiple myeloma, glioblastomas and breast carcinoma.
  • a cancer selected from the group consisting of head and neck squamous cell carcinomas, histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer, non-small cell lung cancer, pancreatic cancer, papillary renal cell carcinoma, liver cancer, gastric cancers, colon cancer, leukemias, lymphomas, multiple myeloma, glioblastomas and breast carcinoma.
  • compounds of formulae (I), (II) and (III) can be used for the treatment of a cancer selected from the group consisting of histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer, pancreatic cancer, liver cancer, gastric cancer, colon cancer, leukemias, lymphomas, multiple myeloma, glioblastomas and breast carcinoma.
  • a cancer selected from the group consisting of histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer, pancreatic cancer, liver cancer, gastric cancer, colon cancer, leukemias, lymphomas, multiple myeloma, glioblastomas and breast carcinoma.
  • compounds of formulae (I), (II) and (III) can be used for the treatment of cancer selected from the group consisting of lymphomas, leukemias and multiple myeloma.
  • the invention provides for the preparation of a medicament comprising a compound of formula (I), (II), (III) or any variations thereof detailed herein for the treatment of lymphoma, leukemia or multiple myeloma.
  • the invention provides for the treatment of lymphoma, leukemia or multiple myeloma, which method comprises administering an effective amount of a compound of formula (I), (II), (III) or any variations thereof detailed herein.
  • compounds of the invention are useful for the treatment of inflammatory diseases and conditions including, but not limited to, lupus (including systemic lupus erythematosus, extra-renal lupus and lupus nephritis), asthma, COPD, rhinitis, multiple sclerosis, IBD, arthritis, gastritis, rheumatoid arthritis, dermatitis, endometriosis, transplant rejection, cardiac infarction, Alzheimer's diseases, diabetes Type II, inflammatory bowel disease, sepsis, and artherosclerosis.
  • the invention provides for the use of a compound of formula (I), (II), (III) or any variations thereof detailed herein for the treatment of an inflammatory condition.
  • the invention provideds for the use of a compound of formula (I), (II), (III) or any variations thereof detailed herein for the preparation of a medicament for the treatment of an inflammatory condition.
  • the invention provides for a compound of formula (I), (II), (III) or any variations thereof detailed herein for the treatment of an inflammatory condition.
  • the invention provides for a method for the treatment of an inflammatory condition, which method comprises administering an effective amount of a compound of formula (I), (II), (III) or any variations thereof detailed herein to a patient in need thereof.
  • the invention provides for the the treatment of an inflammatory condition selected from the group consisting of lupus (including systemic lupus erythematosus, extra-renal lupus and lupus nephritis), COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatisis, endometriosis and transplant rejection, which method comprises administering an effective amount of a compound of formula (I), (II), (III) or any variations thereof detailed herein.
  • an inflammatory condition selected from the group consisting of lupus (including systemic lupus erythematosus, extra-renal lupus and lupus nephritis), COPD, rhinitis, multiple sclerosis, IBD, arthritis, rheumatoid arthritis, dermatisis, endometriosis and transplant rejection, which method comprises administering an effective amount of a compound of formula (I), (II
  • the compounds of formulae (I), (II) and (III) may be employed alone or in combination with other therapeutic agents for treatment.
  • compounds of this invention may be employed alone or in combination with chemotherapeutic agents.
  • compounds of this invention may be employed alone or in combination with anti-inflammatory agents.
  • the compounds of the present invention can be used in combination with one or more additional drugs, for example an anti-inflammatory compound or anti-cancer compounds, that work by a different mechanism of action.
  • the second compound of the pharmaceutical combination formulation or dosing regimen preferably has complementary activities to the compound of this invention such that they do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the compounds may be administered together in a unitary pharmaceutical composition or separately and, when administered separately this may occur simultaneously or sequentially in any order. Such sequential administration may be close in time or remote in time.
  • a compound of formula (I), (II), (III) or any variations thereof detailed herein is combined in a pharmaceutical combination formulation, or dosing regimen as combination therapy, with a second therapeutic compound that has anti-inflammatory or anticancer properties or that is useful for treating an inflammation, immune-response disorder, or hyperproliferative disorder (e.g., cancer).
  • the second therapeutic agent may be a NSAID (Nonsteroidal Anti-Inflammatory Drug) or other anti-inflammatory agent.
  • the second therapeutic agent may be a chemotherapeutic agent.
  • a pharmaceutical composition of this invention comprises a compound of formula (I), (II), (III) or any variations thereof detailed herein in combination with a therapeutic agent such as an NSAID.
  • Aromatic or non-aromatic heterocyclic acid (leq) and HATU (1.2eq) were weighed out and transferred to a vial to which DMF and DIPEA (3-5 eq) were subsequently added.
  • the amine (HNRR) was added to the reaction mixture as a free base or HC1 salt after a short period and the reaction was stirred at room temperature or at 50°C for 2-18 hours. Reaction conversion was monitored by LCMS. Upon completion, the reaction was cooled and the crude product was triterated via addition of water and collected by filtration or extracted with sat ammonium chloride and DCM. Trituration or purification by chromatography gave the amide.
  • reaction mixture was allowed to cool to room temperature and was either filtered thru celite and submitted directly to reverse phase HPLC purification or extracted with dichloromethane and a solution of saturated ammonium chloride before drying, evaporating and submitting to reverse phase purification or using in the subsequent step without purification.
  • Step 1 A solution of diisopropylamine (1.7 eq.) in THF (4.6 mL/mmol) was cooled to - 78 °C, then a solution of n-butyl lithium in hexanes (1.6 M, 1.5 eq.) was added dropwise. After stirring for 5 minutes, this mixture was added via cannula to a -78 °C solution of ethyl diazoacetate (1.6 eq.) and cycloalkylketone (1.0 eq.) in THF (4.6 mL/mmol). The mixture was stirred for 1 hour at -78 °C, then quenched by the addition of sat. NH 4 Cl(aq). The mixture was diluted with water and extracted with EtOAc (2 times). The combined organic extracts were dried (MgS0 4 ) and concentrated in vacuo. Purification by CombiFlash (heptane: EtO Ac) provided the desired product.
  • Step 2 To a solution of product from the previous step (1.0 eq.) in pyridine (4.6 mL/mmol) was added POCI 3 (4.35 eq.) and the mixture was allowed to stir at room temperature overnight. After in vacuo concentration, the mixture was poured onto ice, then extracted with EtOAc (3 times). The combined organic extracts were dried (MgS0 4 ) and concentrated in vacuo. This residue was diluted with octane (2.1 mL/mmol) and heated to 110 °C for two hours. After in vacuo concentration, purification by CombiFlash (heptane:EtOAc) provided the desired product.
  • octane 2.1 mL/mmol
  • Step 3 A solution of product from the previous step (1.0 eq.) in THF (20 mL/mmol) was cooled to 0 °C, then sodium hydride (60%, 3.0 eq.) was added. After stirring for 1 hour, SEMC1 (1.2 eq.) was added and the mixture was allowed to warm to room temperature overnight. After excess hydride was quenched by the addition of water at 0 °C, the mixture was extracted with EtOAc (3 times), the organic extracts dried (MgS0 4 ) and concentrated in vacuo. Purification by CombiFlash (heptane: EtOAc) provided the desired ester containing product.
  • This ester was diluted with THF (5.4 mL/mmol), acetonitrile (5.4 mL/mmol) and water (5.4 mL/mmol) and lithium hydroxide monohydrate (7.0 eq.) was added and the mixture was stirred overnight.
  • the mixture was diluted with water, acidified to pH 3 with 1 N HCl(aq) and extracted with Et 2 0 (once) and 10% MeOH/CH 2 Cl 2 (3 times).
  • the combined organic extracts were dried (MgS0 4 ) and concentrated in vacuo to provide the desired carboxylic acid of sufficient purity to be used directly.
  • Step 1 A solution of cycloalkyl ketone (1.0 eq.) in EtOH (0.5 mL/mmol) was cooled to 0 °C, then sodium ethoxide (21% wt solution in EtOH, 1.1 eq.) was added. To this mixture was added diethyl oxylate (1.0 eq.) and the mixture was allowed to warm to room temperature overnight. In vacuo concentration provided the desired product of sufficient purity to be used directly (yield assumed to be quantitative).
  • Step 2 A solution of product from the previous step (1.0 eq.) in glacial acetic acid (0.5 mL/mmol) was cooled to 0 °C, then hydrazine hydrate (1.1 eq.) was added. After warming to room temperature, the mixture was stirred for 1 hour, then diluted with sat. NaHC0 3 (aq) and extracted with 10% MeOH/CH 2 Cl 2 . The organic extracts were dried (MgS0 4 ) and concentrated in vacuo. Purification by CombiFlash (heptane: EtO Ac) provided the desired tetrahydroindazole- 3-carboxylate.
  • Step 3 Performed in an analogous manner to Step 3 General Procedure X.
  • stereoisomers are separated to give single enantiomers or diastereomers as single, unknown stereoisomers, and are arbitrarily drawn as single isomers. Where appropriate, information is given on separation method and elution time and order.
  • Step 1 Synthesis of ethyl 2-amin -5-chlorothiazole-4-carboxylate
  • Step 3 Synthesis of (ii)-ethyl 5-chloro-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)thiazole-4-carboxylate
  • Step 4 Synthesis of (ii)-5-chloro-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)thiazole-4-carboxamide
  • Step 5 Synthesis of (ii)-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(l- methyl-lH-pyrazol-4-yl)thiazole-4-carboxamide
  • Step 1 Synthesis of l-(3-methoxyphenyl)-4-[(l-methyl-lH-pyrazol-5-yl)amino]-lH-pyrazole-3- carboxylic acid
  • Step 2 Synthesis of l-(3-methoxyphenyl)-4-[(l-methyl-lH-pyrazol-5-yl)amino]-lH-pyrazole-3- carboxamide
  • Step 3 Synthesis of 1 -(3 -hydroxyphenyl)-4-[(l -methyl- lH-pyrazol-5 -yl)amino]-l H-pyrazole-3- carboxamide
  • Step 5 Synthesis of (ii)-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4-(l- methyl-lH-pyrazol-5-ylamino)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of methyl 4-(l ,3-dimethyl-lH-pyrazol-4-yl)-lH-pyrazole-3-carboxylate
  • Step 2 Synthesis of methyl l-(3-bromophenyl)-4-(l,3-dimethyl-lH-pyrazol-4-yl)-lH-pyrazole- 3-carboxylate
  • Step 3 Synthesis of methyl 4-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(3-[2-[(3ii)-3-hydroxy-l- methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-lH-pyrazole-3-carboxylate
  • Step 4 Synthesis of 4-( 1,3 -dimethyl- lH-pyrazol-4-yl)-l -(3- [2- [(3R)-3 -hydroxy- l-methyl-2- oxo rrolidin-3-yl]ethynyl]phenyl)-lH-pyrazole-3-carboxamide
  • Step 2 Synthesis of l-(3-bromophenyl)-4-[(methylcarbamoyl)amino]-lH-pyrazole-3- carboxamide
  • Step 3 Synthesis of l-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-4- [(methylcarbamoyl)amino]-lH-pyrazole-3-carboxarnide
  • Step 1 Synthesis of ethyl l'-ethyl- '-bi(lH-pyrazole)-3-carboxylate
  • Step 2 Synthesis of ethyl l-(3-bromophenyl)-l'-ethyl-4,4'-bi(lH-pyrazole)-3-carboxylate
  • Step 3 Synthesis of (ii)-ethyl 1 '-ethyl- l-(3-((3-hydroxy- l-methyl-2-ox opyrrolidin-3- l)ethynyl)phenyl)-4,4'-bi(lH-pyrazole)-3-carboxylate
  • Step 4 Synthesis of (ii)-l'-ethyl-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)-4,4'-bi(lH-pyrazole)-3-carboxamide
  • Step 1 Synthesis of ethyl l-(3-bromophenyl)-4-(N-ethylacetamido)-lH-pyrazole-3-carboxylate
  • Step 2 Synthesis of l-(3-bromophenyl)-4-(N-ethylacetamido)-lH-pyrazole-3-carboxamide
  • Step 3 Synthesis of l-(3-bromophenyl)-4-(ethylamino)-lH-pyrazole-3-carboxarnide
  • Step 4 Synthesis of 4-(ethylamino)-l-(3-[2-[(3R)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of ethyl 2-amino-5-iodothiazole-4-carboxylate
  • Step 3 Synthesis of ethyl 2-chloro-5-(trifluoromethyl)thiazole-4-carboxylate
  • Step 4 Synthesis of (ii)-ethyl 2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)- -(trifluoromethyl)thiazole-4-carboxylate
  • Step 5 Synthesis of (ii)-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5- (trifluoromethyl)thiazole-4-carboxamide
  • Step 2 Synthesis of ethyl l-(3-bromophenyl)-4-(trifluoromethyl)-lH-pyrazole-3-carboxylate
  • Step 3 Synthesis of ethyl l-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-4-(trifluoromethyl)-lH-pyrazole-3-carboxylate
  • Step 4 Synthesis of (ii)-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4- (trifluoromethyl)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of methyl 4-( 1 ,5 -dimethyl- lH-pyrazol-4-yl)-lH-pyrazole-3 -carboxylate
  • Step 2 Synthesis of methyl l-(3-bromophenyl)-4-(l,5-dimethyl-lH-pyrazol-4-yl)-lH-pyrazole-
  • Step 3 Synthesis of methyl 4-( 1 ,5 -dimethyl- lH-pyrazol-4-yl)-l -(3- [2- [(3R)-3 -hydroxy- 1- methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-lH-pyrazole-3-carboxylate
  • Step 4 Synthesis of 4-( 1 ,5 -dimethyl- lH-pyrazol-4-yl)-l -(3- [2- [(3R)-3 -hydroxy- l-methyl-2- oxopyrrolidin-3-yl]ethynyl]phenyl)-lH-pyrazole-3-carboxarnide
  • Step 1 Synthesis of ethyl 2-(3-[2-[(3R)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-5 - [( 1 -methyl- 1 H-pyrazol- -yl)amino] - 1 ,3 -thiazole-4-carboxylate
  • Step 2 Synthesis of 2-(3-[2-[(3R)-3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5- [(l-methyl-lH-pyrazol-4-yl)amino]-l,3-thiazole-4-carboxylic acid
  • Step 3 Synthesis of (ii)-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-(l- methyl-lH-pyrazol-4-ylamino)thiazole-4-carboxamide
  • Step 1 Synthesis of (3ii)-3-[2-[3-(3-bromo-l ,2,4-thiadiazol-5-yl)-4-fluorophenyl]ethynyl]-3- hydroxy- 1 -methylpyrrolidin-2-one
  • Step 2 Synthesis of 5-(2-fluoro-5-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-l ,2,4-thiadiazole-3-carbonitrile
  • Step 3 Synthesis of (ii)-5-(2-fluoro-5-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)-l ,2,4-thiadiazole-3-carboxamide
  • Step 2 Synthesis of l-(3-methoxyphenyl)-4-[(l-methyl-lH-pyrazol-4-yl)amino]-lH-pyrazole-3- carboxylic acid
  • Step 3 Synthesis of l-(3-methoxyphenyl)-4-[(l-methyl-lH-pyrazol-4-yl)amino]-lH-pyrazole-3- carboxamide
  • Step 4 Synthesis of 1 -(3 -hydroxyphenyl)-4-[(l -methyl- lH-pyrazol-4-yl)amino]-lH-pyrazole-3- carboxamide
  • Step 5 Synthesis of 3-[3-carbamoyl-4-[(l-methyl-lH-pyrazol-4-yl)amino]-lH-pyrazol-l- yl]phenyl trifluoromethanesulfonate
  • Step 6 Synthesis of (ii)-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4-(l- methyl- 1 H-pyrazol-4-ylamino)- 1 H-pyrazole-3-carboxamide
  • Step 4 Synthesis of 3-[3-carbamoyl-4-(pyridin-2-yl)-lH-pyrazol-l -yl]phenyl
  • Step 5 Synthesis of (ii)-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-4- (pyridin-2-yl)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of ethyl 2-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-5-[(oxetan-3-yl)amino]-l,3-thiazole-4-carboxylate
  • Step 2 Synthesis of 2-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)-5- [(oxetan-3-yl)amino]-l,3-thiazole-4-carboxylic acid
  • Step 3 Synthesis of (ii)-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-5-
  • Step 1 Synthesis of (ii)-ethyl 5-ethyl-2-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)thiazole-4-carboxylate
  • Step 1 Synthesis of tert-butyl 3-[methoxy(methyl)carbamoyl]morpholine-4-carboxylate
  • Step 2 Synthesis of tert-butyl 3-[(3-bromophenyl)carbonyl]morpholine-4-carboxylate
  • n-Butyllithium (8 mL, 2M in THF, 1.10 equiv) was added dropwise into a solution of 1 ,3-dibromobenzene (3.44 g, 14.58 mmol, 1.00 equiv) in tetrahydrofuran (200 mL) under nitrogen. The resulting solution was stirred for 2 h at -78°C and then tert-butyl 3- [methoxy(methyl)carbamoyl]morpholine-4-carboxylate (4.00 g, 14.58 mmol, 1.00 equiv) in tetrahydrofuran (100 mL) was added dropwise at -78°C.
  • Step 4 Synthesis of 3-(3-bromophenyl)-l-iodo-4H,6H,7H-imidazo[4,3-c][l ,4]oxazine
  • Step 5 Synthesis of methyl 3-(3-bromophenyl)-4H,6H,7H-imidazo[4,3-c][l ,4]oxazine-l- carboxylate
  • Step 6 Synthesis of methyl 3-(3-[2-[(3R)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- l]ethynyl]phenyl)-4H,6H,7H-imidazo[4,3-c][l,4]oxazine-l-carboxylate
  • Step 7 Synthesis of (ii)-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-6,8- dih dro-5H-imidazo[5 , 1 -c] [1 ,4]oxazine-3-carboxamide
  • Step 2 Synthesis of ethyl 4-cyclopropaneamido-l-(3-[2-[(3ii)-3-hydroxy-l-methyl-2- oxopyrrolidin-3-yl]ethynyl]phenyl)-lH-pyrazole-3-carboxylate
  • Step 3 Synthesis of (ii)-4-(cyclopropanecarboxamido)-l-(3-((3-hydroxy-l-methyl-2- oxopyrrolidin-3-yl)ethynyl)phenyl)-lH-pyrazole-3-carboxamide
  • Step 3 Synthesis of (ii)-4-acetamido-l-(3-((3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of ethyl l-(3-bromophenyl)-4-nitro-lH-pyrazole-3-carboxylate
  • Step 2 Synthesis of ethyl 4-amino-l-(3-bromophenyl)-lH-pyrazole-3-carboxylate
  • Step 3 Synthesis of ethyl 4-amino-l-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-lH-pyrazole-3-carboxylate
  • Step 4 Synthesis of 4-amino-l-(3-[2-[(3ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl]ethynyl]phenyl)-lH-pyrazole-3-carboxamide
  • Step 1 Synthesis of ethyl l-(3-bromophenyl)-4-[(2-fluorocyclopropane)amido]-lH-pyrazole-3- carboxylate
  • Step 2 Synthesis of ethyl 4-[(trans-2-fluorocyclopropane)amido]-l-(3-[2-[(3R)-3-hydroxy-l- methyl-2-oxopyrrolidin-3-yl]ethynyl]phenyl)- -pyrazole-3-carboxylate
  • Step 3 Synthesis of 4-((l ⁇ ,2ii)-2-fluorocyclopropanecarboxarnido)-l-(3-(((ii)-3-hydroxy-l- methyl-2-oxopyrrolidin-3-yl)ethynyl)phenyl)-lH-pyrazole-3-carboxamide and 4-(( ⁇ ?,25)-2- fluorocyclopropanecarboxamido)-l-(3-(((ii)-3-hydroxy-l-methyl-2-oxopyrrolidin-3- yl)ethynyl)phenyl)-lH-pyrazole-3-carboxamide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (I), dans laquelle Q, A1-A8, R4 et R5 sont tels que définis dans la description. Les composés de formule (I) et les compositions pharmaceutiques de ceux-ci sont utiles dans le traitement de maladies et de troubles dans lesquels l'activation indésirable ou la suractivation de la signalisation de NF-kB est observée.
EP16705959.1A 2015-02-25 2016-02-24 Alcools d'alcynyle et leurs procédés d'utilisation Withdrawn EP3262035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015073258 2015-02-25
PCT/EP2016/053805 WO2016135163A1 (fr) 2015-02-25 2016-02-24 Alcools d'alcynyle et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
EP3262035A1 true EP3262035A1 (fr) 2018-01-03

Family

ID=55409848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16705959.1A Withdrawn EP3262035A1 (fr) 2015-02-25 2016-02-24 Alcools d'alcynyle et leurs procédés d'utilisation

Country Status (4)

Country Link
EP (1) EP3262035A1 (fr)
JP (1) JP2018510140A (fr)
CN (1) CN107406427A (fr)
WO (1) WO2016135163A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831720B (zh) * 2017-01-21 2019-04-16 河北科技大学 双-4-(1h-吡唑-1-基)哌啶-1-甲酸叔丁酯的合成方法及其应用
CN114072397A (zh) 2019-05-10 2022-02-18 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
SG11202112994WA (en) 2019-05-31 2021-12-30 Janssen Pharmaceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
CN114258318B (zh) 2019-06-17 2024-09-20 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
WO2022011338A2 (fr) * 2020-07-10 2022-01-13 Origenis Gmbh Modulateurs de kinase et leurs procédés d'utilisation
US20230373985A1 (en) * 2020-07-10 2023-11-23 Origenis Gmbh Kinase modulators and methods of use thereof
CN112209916B (zh) * 2020-10-23 2021-06-01 河北师范大学 一种钌配合物、制备方法和催化用途
US20230416256A1 (en) * 2020-11-12 2023-12-28 Janssen Pharamceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
MX2010013920A (es) * 2008-06-26 2011-02-21 Amgen Inc Alcoholes alquinilicos como inhibidores de cinasas.
BR112013023681A2 (pt) * 2011-03-16 2016-12-13 Hoffmann La Roche compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
TW201512173A (zh) * 2013-08-22 2015-04-01 Hoffmann La Roche 炔基醇及其使用方法

Also Published As

Publication number Publication date
WO2016135163A1 (fr) 2016-09-01
CN107406427A (zh) 2017-11-28
JP2018510140A (ja) 2018-04-12

Similar Documents

Publication Publication Date Title
US9605005B2 (en) Alkynyl alcohols and methods of use
WO2016135163A1 (fr) Alcools d'alcynyle et leurs procédés d'utilisation
EP2091951B1 (fr) Derives de pyrido[2,3-b]pyrazine et [1,8]-naphthyridine en tant qu'inhibiteurs de alk et de c-met
CA2821712C (fr) Composes n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamides substitues en tant qu'inhibiteurs de tyrosine kinase de recepteurs de type iii
AU2019257450A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
WO2016010950A1 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
TW201542520A (zh) 炔基醇及其使用方法
CA2916298A1 (fr) Carboxamides primaires servant d'inhibiteurs de la btk
EP3661931A1 (fr) Composé hétérocyclique
KR20160131119A (ko) TrkA 키나제 억제제, 조성물 및 그의 방법
WO2017089390A1 (fr) Inhibiteurs des janus kinases, leurs compositions et leur utilisation
EP3504206B1 (fr) Dérivés de 2-azabicyclo [3.1.0]hexan-3-one et procédés d'utilisation
EP3562809A1 (fr) Composés pyrazolopyrimidine et leurs procédés d'utilisation
KR20210151833A (ko) Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
TW201429959A (zh) 雜環核荷爾蒙受體調節劑
TW202229273A (zh) 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
CN107848971B (zh) 杂环化合物
KR20160045819A (ko) 알킨일 알코올 및 이용 방법
KR20160045817A (ko) 알킨일 알콜 및 사용 방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180417